Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis

2019601 citationsJournal Article

Authors

Nan Chen · Shanghai Jiao Tong University

Chuan‐Ming Hao · Huashan Hospital

Bi‐Cheng Liu · Zhongda Hospital Southeast University

Hongli Lin · Dalian Medical University

Caili Wang

Changying Xing · Nanjing Medical University

Xinling Liang · Guangdong Academy of Medical Sciences

Abstract

Oral roxadustat was noninferior to parenteral epoetin alfa as therapy for anemia in Chinese patients undergoing dialysis. (Funded by FibroGen and FibroGen [China] Medical Technology Development; ClinicalTrials.gov number, NCT02652806.).

Topics & Keywords

Erythropoietin and Anemia Treatment Blood transfusion and management Dialysis and Renal Disease Management

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 381, Issue 11, pp. 1011-1022

DOI: 10.1056/nejmoa1901713

Field-Weighted Citation Impact: 53.60